Viridian Therapeutics, Inc.\DE

VRDN

Form 4 • Statement of Changes in Beneficial Ownership

SEC Accession Number: 0001193125-26-092036
Filing date: Mar 4, 2026
Earliest execution date: Mar 3, 2026
Reporting Owners: Mahoney Stephen F. (CEO)

Summary

Type

Sell

Net shares

-7,627

% of shares

-18.71%

Amount (USD)

$223,623

Insider confidence score

22.5 out of 100

Negative

  • Large discretionary sell (≥1% of shares)
  • Significant sell amount ($50K+)

Stock transactions

Transaction 1

Security

Common Stock

Action

Exercise

Date

2026-03-03

Code

M

Net shares

+18,357.0

Acquired/Disposed

Acquired

Shares Owned Before

22,400.0

Shares Owned After

40,757.0

Transaction 2

Security

Common Stock

Action

Tax_withhold

Date

2026-03-03

Code

F

Net shares

-7,627.0

Price per Share

$29.32

Amount (USD)

$223,623.64

Acquired/Disposed

Disposed

Shares Owned Before

40,757.0

Shares Owned After

33,130.0

Derivative Transactions

Transaction 1

Security

Stock Option (Right to Buy)

Action

Grant

Date

2026-03-02

Code

A

Net shares

+559,600.0

Acquired/Disposed

Acquired

Shares Owned Before

0.0

Shares Owned After

559,600.0

Transaction 2

Security

Restricted Stock Units

Action

Grant

Date

2026-03-02

Code

A

Net shares

+111,900.0

Acquired/Disposed

Acquired

Shares Owned Before

0.0

Shares Owned After

111,900.0

Transaction 3

Security

Restricted Stock Units

Action

Exercise

Date

2026-03-03

Code

M

Net shares

-18,357.0

Acquired/Disposed

Disposed

Shares Owned Before

73,428.0

Shares Owned After

55,071.0

Filing's footnotes

1. The option vests and becomes exercisable in 48 equal monthly installments following the date of the grant, subject to the Reporting Person's continued service to Issuer through each vesting date. The date of the grant is March 2, 2026.

2. Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of the Issuer.

3. The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 2, 2026, subject to the Reporting Person's continued service to Issuer through each vesting date.

4. The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 3, 2025, subject to the Reporting Person's continued service to Issuer through each vesting date.

5. Includes 1,000 shares acquired under Viridian Therapeutics, Inc.'s 2016 Employee Stock Purchase Plan (the "ESPP") on March 17, 2025 in transactions that were exempt under Rule 16b-3(c).

This page is for informational purposes only. While we strive for accuracy, the summary may contain inaccuracies or omissions. Please refer to the official SEC filing for authoritative information. Open the SEC filing.